Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (271-280 of 785) with videos related to

Pageof 79
Sort By:
Diabetes Care|February 2, 2019
Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME TrialSilvio E Inzucchi, Christoph Wanner, Uwe Hehnke, et al.
European Heart Journal|March 23, 2013
Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry diseaseJohannes Krämer, Markus Niemann, Dan Liu, et al.
European Journal of Preventive Cardiology|May 16, 2017
Prevalence of chronic kidney disease and its determinants in coronary heart disease patients in 24 European countries: Insights from the EUROASPIRE IV survey of the European Society of CardiologyMartin Wagner, Christoph Wanner, Kornelia Kotseva, et al.
European Journal of Heart Failure|December 15, 2010
Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase AWolfram Machann, Frank Breunig, Frank Weidemann, et al.
Plos One|May 30, 2015
Effect of High-Flux Dialysis on Circulating FGF-23 Levels in End-Stage Renal Disease Patients: Results from a Randomized TrialAndreas Schneider, Markus P Schneider, Detlef H Krieter, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 13, 2016
Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D StudyBarbara Kollerits, Christiane Drechsler, Vera Krane, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 1, 2019
Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME TrialMark E Cooper, Silvio E Inzucchi, Bernard Zinman, et al.
Nature Clinical Practice. Nephrology|August 30, 2008
The ISN Clinical Practice Guidelines CommitteeGavin J Becker, Omar Abboud, Ezequiel Bellorin-Font, et al.
Clinical Pharmacology and Therapeutics|July 13, 2017
Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme ReplacementNicolas Guérard, Daniel Oder, Peter Nordbeck, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 18, 2023
Guardians For Health: A Practical Approach to Improving Quality of Life and Longevity in People with Type 2 DiabetesNaresh Kanumilli, Javed Butler, Konstantinos Makrilakis, et al.
Pageof 79

Showing results (271-280 of 785) with videos related to

Sort By:
Pageof 79
Diabetes Care|February 2, 2019
Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME TrialSilvio E Inzucchi, Christoph Wanner, Uwe Hehnke, et al.
European Heart Journal|March 23, 2013
Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry diseaseJohannes Krämer, Markus Niemann, Dan Liu, et al.
European Journal of Preventive Cardiology|May 16, 2017
Prevalence of chronic kidney disease and its determinants in coronary heart disease patients in 24 European countries: Insights from the EUROASPIRE IV survey of the European Society of CardiologyMartin Wagner, Christoph Wanner, Kornelia Kotseva, et al.
European Journal of Heart Failure|December 15, 2010
Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase AWolfram Machann, Frank Breunig, Frank Weidemann, et al.
Plos One|May 30, 2015
Effect of High-Flux Dialysis on Circulating FGF-23 Levels in End-Stage Renal Disease Patients: Results from a Randomized TrialAndreas Schneider, Markus P Schneider, Detlef H Krieter, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 13, 2016
Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D StudyBarbara Kollerits, Christiane Drechsler, Vera Krane, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 1, 2019
Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME TrialMark E Cooper, Silvio E Inzucchi, Bernard Zinman, et al.
Nature Clinical Practice. Nephrology|August 30, 2008
The ISN Clinical Practice Guidelines CommitteeGavin J Becker, Omar Abboud, Ezequiel Bellorin-Font, et al.
Clinical Pharmacology and Therapeutics|July 13, 2017
Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme ReplacementNicolas Guérard, Daniel Oder, Peter Nordbeck, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 18, 2023
Guardians For Health: A Practical Approach to Improving Quality of Life and Longevity in People with Type 2 DiabetesNaresh Kanumilli, Javed Butler, Konstantinos Makrilakis, et al.
Pageof 79